Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 18 of 18 for “"AChEI"”.
-
The AChEI and the inflammation-induced neuropathological changes in mice
… deficits. Acetylcholinesterase inhibitors (AChEI) have been the most common prescriptions for AD since 1993. Donepezil is the most commonly used AChEI in the treatment of mild, moderate and severe AD cases and has less adverse effects. According to another hypothesis, the myelin hypothesis, …
-
Predictors of Response to Acetylcholinesterase Inhibitors: An Observational Case Register-Based Cohort Study
Background: Acetylcholinesterase inhibitors (AChEIs) are a key component of dementia care. Longitudinal cognitive change in patients before and after AChEI initiation has never been described previously, although individual responses have been described as heterogeneous. Predictors of such …
-
Demenzspezifische medikamentöse Behandlung mit Acetylcholinesterase-Hemmern und Memantine – Unter- und Fehlversorgung?
… Versorgung mit Acetylcholinesterase-Hemmern (AChEI) und Memantine bei hausärztlich betreuten Alzheimer- bzw. Demenzpatienten. Des Weiteren sollten Determinanten auf ihre Assoziation mit einer Einnahme/Verschreibung von Antidementiva identifiziert werden. Die vorliegende Untersuchung basiert …
-
Mild and Convenient Methods to Prepare N-Alkyl Tacrines
… disturbances. Acetylcholinesterase inhibitors (AChEI) are the mainstay for the treatment of AD. Acetylcholinesterase (AChE) catalyzes the hydrolysis of acylcholinesters with a relative specificity for acetylcholine (ACh). Observation of a deficiency of cholinergic neurotransmission in AD led to …
-
Experimental and Computational Investigation of Tacrine-Based Inhibitors of Acetylcholinesterase
… disease (AD) patients; four AChE inhibitors (AChEI) have been approved by the FDA for this purpose. The first AChEI approved for the palliative treatment of AD-related memory loss was 9-amino-1,2,3,4-tetrahydroacridine (tacrine). Inhibition of AChE may present either therapeutic or toxic …
-
Validation of brief cognitive tests in mild cognitive impairment, Alzheimer's disease and dementia with Lewy bodies.
… treatment with acetylcholinesterase inhibitors (AChEI) in patients with AD. II. Easy and quick interpretations of the MMSE, clock drawing and cube copying differentiated patients with DLB from patients with AD. III. AQT was twice as sensitive as the MMSE in detecting treatment response to AChEI …
-
Acetylcholine and posttraumatic stress disorder.
… administering acetylcholinesterase inhibitors (AChEI) to people suffering these symptoms have been demonstrated. Donepezil hydrochloride, a reversible inhibitor of the enzyme acetylcholinesterase, is used in the treatment of conditions with difficulties in cognitive function, but has not been …
-
Δερεύνηση του ανοσοβιοχημικού προφίλ ασθενών με έκπτωση των γνωσιακών λειτουργιών και συσχέτιση με τα νευροψυχιατρικά συμπτώματα
… or not ([NA]) acetylcholinesterase inhibitor (AChEI) andcompared among themselves and with the group of controls. Six months after startingtreatment with AChEI, a subgroup of [NA] has been re-assessed clinically and newblood measurements have been performed. Five years later there was a …
-
Präsynaptische Wirkungen von Cholinesterase-Hemmstoffen im Neocortex des Menschen und der Ratte
… hauptsächlich mit <br>Cholinesterase-Hemmern (AChEI) behandelt. Diese könnten jedoch auch indirekt - <br>nach der angestrebten Erhöhung der endogenen ACh-Spiegel - über muskarinische <br>Autorezeptoren die ACh-Freisetzung im Gehirn verringern. Um diesen klinisch <br>unerwünschten, "paradoxen" …
-
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitor use
… of the three acetylcholinesterase inhibitors (AChEIs) used in the treatment of Alzheimer’s Disease (AD) and related dementias, may be associated with a greater risk of ALQTS and malignant arrhythmias. Only a limited number of studies have generated relevant information, and no population-based …
-
Development and In Vitro Evaluation of Donepezil Hybrid Systems for Nose-to-Brain Delivery
… αναστολέας της ακετυλοχολινεστεράσης (AChEI) που χρησιμοποιείται για τη θεραπεία της ήπιας έως μέτριας βαρύτητας άνοιας που σχετίζεται με τη νόσο του Alzheimer (AD). Αρχικά, η DH εγκλείστηκε σε υβριδικές κολλοειδείς διασπορές που αποτελούνταν από εμπορικά διαθέσιμα συμπολυμερή όπως τα …
-
THE MECHANISMS AND PHARMACOLOGY OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS IN THE CENTRAL NERVOUS SYSTEM
… α7 nAChR agonists or inhibitors of ACh esterase (AChEI). However, nicotinic agonists desensitize α7 nAChRs while AChEI produces side effects limiting their overall clinical and pre-clinical effectiveness. These limitations can be avoided by using a novel class of drugs; type-II positive allosteric …
-
Study of Polyphenols and Naphthalimide Analogs As Inhibitors of Amyloid- β Protein Aggregation In Alzheimer'S Disease
… analog acetylcholinesterase inhibitior (AChEI), G-II-19, synthesized by Jie Gao in Dr. Chapman's laboratory, a group of naphthalimide analogs was synthesized as potential dual-function inhibitors for AChE and Aβ aggregation. Results identify several naphthalimide analogs as novel, …
-
Cholinergic enhancement of cell proliferation and differentiation in the postnatal neurogenic niche of the intact and demyelinated spinal cord.
… ACh using an acetylcholinesterase inhibitor (AChEI) donepezil decreased the number of proliferating cells (visualised using the thymidine analogue EdU) in the CC in vivo and in vitro compared to control. Potentiating the effect of ACh transmission on α7 nicotinic acetylcholine receptors …
-
THE HUMAN-RESTRICTED DUPLICATED FORM OF THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR, CHRFAM7A: TRANSCRIPTIONAL REGULATION, ROLE IN INFLAMMATION AND POTENTIAL PHARMACOLOGICAL IMPLICATIONS
… Moreover, we have investigated the effect of the AChEI Donepezil on CHRFAM7A and CHRNA7 transcription in THP-1 cells, human primary macrophages and SH-SY5Y cells, collecting new insights about the possible role of the α7dup gene as a pharmacological target in AD therapy.
-
Development and in vitro/ in vivo evaluation of nasal films as nose-to-brain delivery systems in neurodegenerative diseases
… of DH as an Acetylcholinesterase Inhibitor (AChEI) and a Sigma-1 receptors (Sig-1R) agonist, the second objective of this PhD thesis focuses on the concept of drug repurposing. Specifically, the possible use of DH in the treatment of the Krabbe disease (KD) was explored. KD is a demyelinating …
-
Multi-Targeting Derivatives For Alzheimer’s Disease: Utilization of Quinazoline Ring Scaffolds
… were considered moderate. The most active AChEI and ROS scavenger across the research program was discovered within this series. This chapter also included the bulk of synthetic and biochemical assessment protocols/methodologies. Chapter four describes the design, development and evaluation …
-
In silico Studien zu Bis-Tacrinen, Chinazolinen und Chinazolinonen sowie Synthese von Chinazoliniumverbindungen als Inhibitoren von Cholinesterasen
… die Gabe von Acetylcholinesterase- Inhibitoren (AChEI) symptomatisch behandelt. Durch die AChE-Hemmung steht mehr Acetylcholin (ACh) für die Neurotransmission zur Verfügung. Bei Progression der Erkran-kung nimmt der Anteil an AChE drastisch ab, so dass die Enzymisoform Butyrylcholin- esterase …